Insider Selling: Cara Therapeutics Inc (NASDAQ:CARA) Insider Sells $247,390.00 in Stock

Cara Therapeutics Inc (NASDAQ:CARA) insider Frederique Ph.D. Menzaghi sold 8,996 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $27.50, for a total transaction of $247,390.00. Following the completion of the transaction, the insider now owns 119,886 shares in the company, valued at approximately $3,296,865. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Frederique Ph.D. Menzaghi also recently made the following trade(s):

  • On Monday, July 1st, Frederique Ph.D. Menzaghi sold 20,000 shares of Cara Therapeutics stock. The stock was sold at an average price of $21.90, for a total transaction of $438,000.00.
  • On Wednesday, May 29th, Frederique Ph.D. Menzaghi sold 11,397 shares of Cara Therapeutics stock. The stock was sold at an average price of $21.19, for a total transaction of $241,502.43.

Cara Therapeutics stock opened at $25.91 on Monday. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 0.04. Cara Therapeutics Inc has a 12 month low of $12.19 and a 12 month high of $27.55. The stock has a 50 day moving average of $21.43. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -12.58 and a beta of 2.25.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.01). Cara Therapeutics had a negative return on equity of 67.30% and a negative net margin of 443.71%. The company had revenue of $4.38 million during the quarter, compared to analysts’ expectations of $5.14 million. As a group, sell-side analysts forecast that Cara Therapeutics Inc will post -2.38 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. New York State Common Retirement Fund lifted its position in shares of Cara Therapeutics by 2.0% during the 4th quarter. New York State Common Retirement Fund now owns 30,700 shares of the biopharmaceutical company’s stock valued at $399,000 after buying an additional 600 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Cara Therapeutics by 5.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 14,557 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 814 shares in the last quarter. Rathbone Brothers plc lifted its position in shares of Cara Therapeutics by 6.3% during the 1st quarter. Rathbone Brothers plc now owns 17,000 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 1,000 shares in the last quarter. California Public Employees Retirement System lifted its position in shares of Cara Therapeutics by 1.4% during the 4th quarter. California Public Employees Retirement System now owns 86,798 shares of the biopharmaceutical company’s stock valued at $1,128,000 after buying an additional 1,198 shares in the last quarter. Finally, TCG Advisors LP purchased a new position in shares of Cara Therapeutics during the 1st quarter valued at approximately $30,000. Hedge funds and other institutional investors own 56.10% of the company’s stock.

Several equities research analysts have commented on CARA shares. BidaskClub lowered Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 13th. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. HC Wainwright upped their price objective on Cara Therapeutics from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. Needham & Company LLC upped their price objective on Cara Therapeutics from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. Finally, Laidlaw upped their price objective on Cara Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $25.31.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Further Reading: Current Ratio

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.